marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Collegium Pharmaceutical Balance Sheet 2011-2024 | COLL
Annual Balance Sheet Collegium Pharmaceutical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-232 M | -165 M | -178 M | 36.2 M | -159 M | -135 M | -117 M | -149 M | -88.9 M | 11.4 M | -6.58 M | - | - |
Long Term Debt |
6.12 M | 7.11 M | 7.95 M | 210 M | 7.67 M | 9.86 M | - | 1.48 M | 4.15 M | 6.81 M | 640 K | - | - |
Long Term Debt Current |
988 K | 1.11 M | 814 K | 730 K | 656 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 17.1 M | 10.5 M | - | 1.51 M | 4.21 M | 6.91 M | 834 K | - | - |
Total Current Liabilities |
458 M | 434 M | 280 M | 239 M | 202 M | 189 M | 31.5 M | 25.6 M | 8.43 M | - | - | - | - |
Total Liabilities |
948 M | 979 M | 489 M | 458 M | 219 M | 200 M | 31.5 M | 27.1 M | 12.6 M | 17.3 M | 3.45 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 4.94 M | - | - | - | - | - |
Retained Earnings |
-233 M | -281 M | -256 M | -333 M | -360 M | -337 M | -298 M | -223 M | -129 M | -102 M | -80.5 M | - | - |
Total Assets |
1.14 B | 1.17 B | 692 M | 644 M | 306 M | 291 M | 136 M | 162 M | 97.7 M | 5.09 M | 9.03 M | - | - |
Cash and Cash Equivalents |
239 M | 174 M | 186 M | 174 M | 170 M | 147 M | 119 M | 153 M | 95.7 M | 1.63 M | 7.55 M | - | - |
Book Value |
195 M | 195 M | 203 M | 186 M | 87.4 M | 91.6 M | 104 M | 135 M | 85.1 M | -12.2 M | 5.58 M | - | - |
Total Shareholders Equity |
195 M | 195 M | 203 M | 186 M | 87.4 M | 91.6 M | 104 M | 135 M | 85.1 M | -89.3 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Collegium Pharmaceutical
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5.91 M | 5.59 M | 6.12 M | 6.38 M | 6.63 M | 6.87 M | 7.11 M | 7.35 M | - | 7.91 M | 7.95 M | 8.17 M | 8.37 M | 8.57 M | 8.76 M | 8.76 M | 8.76 M | 8.76 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | - | - | - | - | 4.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.4 B | 837 M | 948 M | 999 M | 1.01 B | 1.03 B | 979 M | 1 B | - | 1.05 B | 489 M | 491 M | 461 M | 476 M | 458 M | 458 M | 458 M | 458 M | 219 M | 219 M | 219 M | 219 M | 200 M | 200 M | 200 M | 200 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-177 M | -186 M | -233 M | -265 M | -286 M | -299 M | -281 M | -274 M | - | -269 M | -256 M | -231 M | -239 M | -312 M | -333 M | -333 M | -333 M | -333 M | -360 M | -360 M | -360 M | -360 M | -337 M | -337 M | -337 M | -337 M | -298 M | -298 M | -298 M | -298 M | -223 M | -223 M | -223 M | -223 M | -129 M | -129 M | -129 M | -129 M | -102 M | -102 M | -102 M | -102 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.64 B | 1.05 B | 1.14 B | 1.18 B | 1.21 B | 1.21 B | 1.17 B | 1.2 B | - | 1.25 B | 692 M | 742 M | 714 M | 646 M | 644 M | 644 M | 644 M | 644 M | 306 M | 306 M | 306 M | 306 M | 291 M | 291 M | 291 M | 291 M | 136 M | 136 M | 136 M | 136 M | 162 M | 162 M | 162 M | 162 M | 97.7 M | 97.7 M | 97.7 M | 97.7 M | 5.09 M | 5.09 M | 5.09 M | 5.09 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
39 M | 173 M | 239 M | 259 M | 284 M | 269 M | 174 M | 134 M | 123 M | 107 M | 186 M | 193 M | 203 M | 183 M | 174 M | 174 M | 174 M | 174 M | 170 M | 170 M | 170 M | 170 M | 147 M | 147 M | 147 M | 147 M | 119 M | 119 M | 119 M | 119 M | 153 M | 153 M | 153 M | 153 M | 95.7 M | 95.7 M | 95.7 M | 95.7 M | 1.63 M | 1.63 M | 1.63 M | 1.63 M | 7.55 M | - | - | - | 11.9 M | - | - | - | - | - | - | - |
Book Value |
234 M | 217 M | 195 M | 179 M | 201 M | 180 M | 195 M | 197 M | - | 196 M | 203 M | 251 M | 253 M | 170 M | 186 M | 186 M | 186 M | 186 M | 87.4 M | 87.4 M | 87.4 M | 87.4 M | 91.6 M | 91.6 M | 91.6 M | 91.6 M | 104 M | 104 M | 104 M | 104 M | 135 M | 135 M | 135 M | 135 M | 85.1 M | 85.1 M | 85.1 M | 85.1 M | -12.2 M | -12.2 M | -12.2 M | -12.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
234 M | 217 M | 195 M | 179 M | 201 M | 180 M | 195 M | 197 M | 198 M | 196 M | 203 M | 251 M | 253 M | 170 M | 186 M | 186 M | 186 M | 186 M | 87.4 M | 87.4 M | 87.4 M | 87.4 M | 91.6 M | 91.6 M | 91.6 M | 91.6 M | 104 M | 104 M | 104 M | 104 M | 135 M | 135 M | 135 M | 135 M | 85.1 M | 85.1 M | 85.1 M | 85.1 M | -89.3 M | -89.3 M | -89.3 M | -89.3 M | -68.2 M | - | - | - | -61.4 M | - | - | - | - | - | - | - |
All numbers in USD currency